The focus is on 1177.HK stock after Sino Biopharmaceutical Limited closed at HKD 6.25 on the HKSE on 18 Mar 2026 ahead of an earnings release scheduled for 19 Mar 2026. Trading volume reached 49,591,661.00 shares with a one-day gain of 2.63%, reflecting cautious positioning ahead of the report. Investors will watch EPS of 0.25 and a trailing PE of 24.20 for guidance on margins and growth. This earnings spotlight connects the near-term price move to fundamentals and the company’s guidance expectations.
Earnings snapshot for 1177.HK stock
Sino Biopharmaceutical (1177.HK) reports on 19 Mar 2026 after the HKSE close; the market is pricing in reaction risk after today’s close at HKD 6.25. Last reported EPS is 0.25 and the company’s earnings announcement is set for 2026-03-19T04:10:00-04:00, which investors should map to Hong Kong trading hours for catalysts.
Price reaction and technicals for 1177.HK stock
Price opened at HKD 6.10, traded between HKD 6.04 and HKD 6.28, and closed HKD 6.25 with volume 49,591,661.00, below the 50-day average of 6.48 and 200-day average of 6.86. Technicals show RSI 44.09 and MACD -0.13, signalling neutral momentum and limited trend conviction ahead of earnings.
Valuation and fundamentals for 1177.HK stock
Sino Biopharmaceutical carries a trailing PE of 24.20, a PB ratio near 2.87, and EPS of 0.25, versus Healthcare sector average PE 30.85 and PB 2.38, suggesting a relative valuation discount on earnings multiple. Key metrics include market cap HKD 108208618021.00, cash per share 1.10, and dividend per share 0.08, which support a defensive income element amid R&D investment of about 18.64% of revenue.
Meyka AI grade and model forecast for 1177.HK stock
Meyka AI rates 1177.HK with a score of 68.90 out of 100: Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month target of HKD 10.77, implying an upside of 72.32% from the current price HKD 6.25; forecasts are model-based projections and not guarantees.
Analyst context and peer comparison for 1177.HK stock
Company ratings show a recent score of B+ (2026-03-17) with a neutral recommendation and mixed metric signals: strong ROE/ROA but weaker DE and PE scores. Compare peer metrics and competitive positioning via Investing.com comparisons to see margin and growth differences Investing.com peer compare 1177 and Investing.com Hansoh compare.
Risks and catalysts for 1177.HK stock outlook
Near-term catalysts include the 19 Mar 2026 earnings release, guidance on R&D spend, and sales traction in oncology and chronic disease lines. Risks include slower operating cash flow, inventory days of 137.80, and margin pressure; monitor management commentary for FY guidance and any one-off investment gains that can swing short-term results.
Final Thoughts
Key takeaways for 1177.HK stock: Sino Biopharmaceutical closed at HKD 6.25 on 18 Mar 2026 with 49,591,661.00 shares traded as the market waits for the 19 Mar 2026 earnings print. Fundamentals show EPS 0.25, PE 24.20, PB 2.87, and market cap HKD 108208618021.00, which look reasonable versus the Healthcare sector. Meyka AI’s model projects a 12-month level of HKD 10.77, an implied upside of 72.32%, while the short-term monthly and quarterly forecasts sit at HKD 6.66 and HKD 7.09 respectively. Our Meyka grade is 68.90/100 (B, HOLD), reflecting mixed signals across growth, margins and leverage. Investors should watch the earnings beat-or-miss, guidance cadence, and any revision to R&D or investment income assumptions before adjusting position sizes. Remember forecasts are model-based projections and not guarantees; use earnings results to re-check valuation and catalysts before acting. Meyka AI provided the analysis as an AI-powered market analysis platform.
FAQs
When will Sino Biopharmaceutical (1177.HK stock) report earnings?
Sino Biopharmaceutical is scheduled to announce earnings on 19 Mar 2026. Investors should check the HKSE timetable and company release for the exact Hong Kong local time and monitor guidance comments that could move 1177.HK stock.
What is the current valuation of 1177.HK stock?
At close on 18 Mar 2026 1177.HK stock traded at HKD 6.25 with a trailing PE of 24.20 and PB of 2.87, below the Healthcare sector PE average of 30.85.
What does Meyka AI forecast for 1177.HK stock?
Meyka AI’s forecast model projects a 12-month target of HKD 10.77 for 1177.HK stock, implying about 72.32% upside from HKD 6.25. Forecasts are projections and not guarantees.
What are the main risks to 1177.HK stock ahead of earnings?
Main near-term risks for 1177.HK stock include weaker-than-expected sales, margin pressure from higher R&D, slower operating cash flow, and inventory build that could compress near-term earnings.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)